INCY News and Press, Incyte Corporation From 12/10/22

- Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi ® ) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF) - Initial results of a Phase 1/2 study evaluating the safety and tolerability...

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology PR Newswire – Treatment with axatilimab resulted in an overall response rate (ORR) of 67% across all pat...

Incyte (NASDAQ:INCY) and CMS Aesthetics, a dermatology medical aesthetic company and subsidiary of CMS (HKEX: 00867), today announced that the companies have entered into a Collaboration and License Agreement for the development and commercialization of ruxolitinib cream, a novel cream formulatio...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips You’ll often hear people say that bear markets are great for finding bargains, and that’s true. With the exception of energy, every major sector is in the red for the year. For its part, the iShares Biotechnolo...

Incyte ( NASDAQ: INCY ) and Mirati Therapeutics ( NASDAQ: MRTX ) entered a clinical trial collaboration and supply agreement. The companies will evaluate a combination of Incyte's small molecule PD-L1 inhibitor INCB99280 and Mirati's KRAS G12C sel...

Incyte (NASDAQ:INCY) and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced a clinical trial collaboration and supply agreement to investigate the combination of INCB99280, Incyte’s small molecule PD-L1 inhibitor, and adagrasib ...

Incyte (Nasdaq:INCY) today announced that abstracts featuring data from its oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston and virtually. “We are proud of the progress be...

Equity markets are deep in the red for the year, and so is the broader biotech industry. But some drugmakers have delivered solid performances over the past 10 months. That's the case with Vertex Pharmaceuticals (NASDAQ: VRTX) and Incyte (NASDAQ: INCY) . Both companies h...

- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company’s LIMBER studies evaluating ruxolitinib in combination with parsaclisib and its ALK2 and BET inhibitors to be pres...

Summary Incyte reported 20% y/y product revenue growth in Q3 2022. Opzelura revenue grew $38 million y/y. Opzelura revenue is likely to grow quickly in Q4 and in 2023. Incyte ( INCY ) is a large-cap pharmaceutical company known mainly for Jakafi, a JAK inhibitor ...